Cefazolin surgical prophylaxis in obesity: a body composition-driven population pharmacokinetic approach
Open Access
- 1 July 2026
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0167725
Abstract
Cefazolin serves as the antibiotic choice for surgical prophylaxis to prevent surgical site infection, yet consensus on dosing guidelines for patients with obesity is not well defined. To quantify cefazolin exposure in plasma and subcutaneous adipose tissue during abdominal surgery, and to build a popPK model comparing standard anthropometrics, calculated body-composition metrics, and directly measured body-composition values as predictors of interindividual variability. A single center prospective study was conducted at Robert Wood Johnson Barnabas University Hospital, NJ, USA. Institutional standard for dosing was 2 g < 120 kg, or 3 g of cefazolin for subjects ≥ 120 kg for 101 adult subjects. Serial blood samples and subcutaneous adipose tissue samples were collected for the assessment of cefazolin concentration. All subjects received body composition assessments. Cefazolin concentrations in plasma remained within the therapeutic range in all stratification groups, yet subcutaneous adipose tissue concentrations failed to meet therapeutic cut offs, with 2- to 8.5-fold decrease in target attainment in subjects with increasing body fat percentages and BMI. A three-compartment biophase model best characterized our data and served as our base popPK model. Stepwise covariate modeling of measured body composition metrics outperformed both calculated body composition metrics and standard anthropomorphic values. The results support the claim that existing weight-based dosing methods fall short at the site of action, while simultaneously providing a proof of concept for the first in-human body composition informed popPK model. Measured body composition metrics can enhance characterization of cefazolin prophylactic exposure for subjects with obesity receiving abdominal surgery.Keywords
Funding Information
- National Institutes of Health (R01GM124046)
This publication has 62 references indexed in Scilit:
- Dose optimization of cefazolin in South African children undergoing cardiac surgery with cardiopulmonary bypassCPT: Pharmacometrics & Systems Pharmacology, 2024
- Morphomics‐informed population pharmacokinetic and physiologically‐based pharmacokinetic modeling to optimize cefazolin surgical prophylaxisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Comprehensive guidance for antibiotic dosing in obese adults: 2022 updatePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgeryPharmacology Research & Perspectives, 2018
- Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017JAMA Surgery, 2017
- Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean DeliveryThe Journal of Clinical Pharmacology, 2016
- The effect of obesity on antibiotic treatment failure: a historical cohort studyPharmacoepidemiology and Drug Safety, 2013
- Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft‐Gault EquationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Surgical Site Infections and Cost in Obese Patients Undergoing Colorectal SurgeryArchives of Surgery, 2011
- Pharmacokinetics and protein binding of cefazolin in morbidly obese patientsEuropean Journal of Clinical Pharmacology, 2011